HypertensionMechanistic study
Evaluating the Consequences of a Hypertension Management Incentive
- quasi-experimental difference-in-differences study
- large US health system
Authors' conclusion
This study’s findings suggest that the addition a quality metric and financial incentive to physicians’ contracts in a large health system had little impact on measured outcomes in the overall population of patients with hypertension. For patients with marginally high blood pressure, the incentive was associated with increased documented hypertension control because of selective remeasurement of blood pressure, decreased medication adjustments, and increased cardiovascular hospitalizations.
Study context
- Population
- Patients with previously diagnosed hypertension, aged 18 to 85 years, with encounters at eligible primary care practicespatients with hypertension, 770,907 encounters at 103 primary care practices
- Participants
- 334,364 patients
- Comparison
- practices that did vs those that did not adopt the financial incentive
- practices that didn = 63
Main finding
As reported in the abstract
Blood pressure remeasurement (overall population)
Difference in probability
1.9 percentage points [pp]
95% CI 0.7–3.1
P = 0.002
practices that did vs those that did not adopt the financial incentive
difference in probability 1.9 percentage points [pp] (95% CI 0.7–3.1); P = 0.002
Further findings
| Outcome | difference in probability (pp) (95% CI) | P value | |
|---|---|---|---|
| Blood pressure documented as controlled (marginally high blood pressure subgroup, initial systolic 140-145 mm Hg) · increased with the financial incentive | 4.1 (2.1–6.0) | P < 0.001 | |
| Blood pressure remeasurement (marginally high blood pressure subgroup) · increased with the financial incentive | 5.6 (2.9–8.3) | P < 0.001 | |
| −50510Difference, pp (linear scale) |
| Outcome | difference in probability (pp) (95% CI) | P value |
|---|---|---|
| Existing antihypertensive medication dose increased (marginally high blood pressure subgroup) · reduced | −1.1 (−2.0 to −3.0) | P = 0.01 |
Safety
| Outcome | difference in risk (pp) (95% CI) | P value | |
|---|---|---|---|
| Hospitalization for stroke or ACS (marginally high blood pressure subgroup) · 3 months; 1 year — practices that did vs those that did not adopt the financial incentive · 3-month risk increased | 0.25 (0.07–0.44) | P = 0.005 | |
| −0.200.20.40.6Difference, pp (linear scale) |
| Outcome | excess risk (pp) (95% CI) | P value |
|---|---|---|
| Hospitalization for stroke or ACS (marginally high blood pressure subgroup) · 3 months; 1 year — practices that did vs those that did not adopt the financial incentive · at 1 year | 0.52 (0.17–0.87) | P = 0.008 |
Original publication
Evaluating the Consequences of a Hypertension Management Incentive. JAMA Intern Med. Published 1 August 2026. doi:10.1001/jamainternmed.2026.1637
Summarised from the published abstract; every number is checked against it